Formosa Pharmaceuticals

Formosa Pharmaceuticals is a clinical-stage biotech with assets in ophthalmology and oncology. Formosa’s flagship asset is clobetasol propionate ophthalmic suspension 0.05% (APP13007), which was approved by the US FDA in March 2024, and subsequently launched in September 2024, for the treatment of ocular inflammation and pain following ocular surgery. This novel topical corticosteroid formulation was developed using

Formosa’s proprietary APNT formulation technology, which operates on the principle of API particle size reduction using generally recognised as safe (GRAS) reagents to yield homogeneous and stable aqueous formulations.

The company’s stock is publicly traded on the Taiwan Stock Exchange. It was founded in 2010 and is based in northern Taiwan.